Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-01-24
2006-01-24
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S387100, C530S387300, C530S387900, C530S388100, C530S388700, C530S388750, C530S388220, C424S130100, C424S133100, C424S134100, C424S141100, C424S143100, C424S154100, C435S007100, C435S007210
Reexamination Certificate
active
06989145
ABSTRACT:
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
REFERENCES:
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 5932703 (1999-08-01), Godiska et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6245332 (2001-06-01), Butcher et al.
patent: 6488930 (2002-12-01), Wu et al.
patent: 6498015 (2002-12-01), Godiska et al.
patent: 2002/0019341 (2002-02-01), Butcher et al.
patent: 2002/0160015 (2002-10-01), Wells et al.
patent: 2002/0187930 (2002-12-01), Wells et al.
patent: WO 96/23068 (1996-08-01), None
patent: WO 97/10354 (1997-03-01), None
patent: WO 99/15666 (1999-04-01), None
patent: WO 99/25380 (1999-05-01), None
patent: WO 00/00219 (2000-01-01), None
patent: WO 00/41724 (2000-07-01), None
patent: WO 00/42074 (2000-07-01), None
patent: WO 00/67791 (2000-11-01), None
Bendig Methods: A Companion to Methods in Enzymology 1995; 8:83-93.
Yoneyama et al. J. Clin. Invest. 1998; 102(11):1933-1941.
Suzuki et al. Int. Immunol. 1999; 11(4):553-559.
International Immunology, vol. 11, No. 4, Apr. 1999, “Instruction to Authors”.
Chuntharapai et al. Meth. Enzymol. 1997; 288:15-27.
Imai, et al., “Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine”, 1999, International Immunology, vol. 11, No. 1, pp. 81-88.
Andrew et al., J. Immunol. Jan. 1, 2001. vol. 166, No. 1, p. 103-111.
Imai et al, Int. Immunol. 1999, vol. 11, No. 1, p. 81-88.
Landolfi et al, J. Immunol. Feb. 1, 2001, vol. 166, No. 3, p. 1748-1754.
He et al, J. Immunol. Jan. 15, 1998, vol. 160, No. 2 p. 1029-1035.
Brown et al Proc. Natl. Acad. Sci. USA Apr. 1, 1991, vol. 88, No. 7, 2663-2667.
Co et al Proc. Natl. Acad. Sci. USA Apr. 1, 1991, vol. 88, No. 7, p. 2869-2873.
Junghans et al Cancer Res. 199, vol. 50, No. 5, p. 1495-1502.
Power et al J. of Biological Chemistry, vol. 270, No. 33, Aug. 18, 1995, pp. 19495-19500 “Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Line”.
Jones et al Blood, vol. 96, No. 2, Jul. 15, 2000, pp. 685-690 “Expression pattern to T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma”.
Mueller et al J. of Immunology, vol. 144, No. 4, Feb. 15, 1990, pp. 1382-1386 “Enhancement of Antibody-Dependent Cytotoxicity with a Chimeric Anti-GD2 /Antibody”.
Riechmann et al Nature, vol. 332, Mar. 24, 1988 pp. 323-327, “Reshaping human antibodies for therapy”.
van den Berg et al Am. J. of Pathology, vol. 154, No. 6, Jun. 1999, pp. 1685-1691 “High Expression of the CC Chemokine TARC in Reed-Sternberg Cells”.
D'Ambrosio et al J. of Immunology, Cutting Edge, 0022-1767/98/502.00, pp. 5111-5115 “Cutting Edge: Selective Up-Regulation of Chemokine Receptors CCR4 and CCR8 upon Activation of Polarized . . . ”.
Bonecchi et al J. Exp. Med., vol. 87, No. 1, Jan. 5, 1998, pp. 129-134 “Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (TH1s) and TH2s”.
Youn et al, Blood, vol. 89, No. 12, Jun. 1997, pp. 4448-4460 Molecular Cloning and Characterization of a cDNA, CHEMR1, Encoding a Chemokine Receptor with a Homology to the Human C-C Chemokine Receptor, CCR-4.
Frade et al J. Clin. Invest., vol. 100, No. 3, Aug. 1997, 497-502 Chemokine Receptors and HIV-1 Infection The Amino-terminal Domain of the CCR2 Chemokine Receptor Acts as Coreceptor for HIV-1 Infection.
Sims, et al., “A Humanized CD18 Antibody Can Block Function without cell Destruction”,The Journal of Immunology, vol. 151, No. 4 (1993), pp. 2177-2335.
Brams et al., “A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation”,Int. Immunopharmacol., (2001); vol. 1, pp. 277-294.
Furuya Akiko
Hanai Nobuo
Nakamura Kazuyasu
Niwa Rinpei
Sakurada Mikiko
Fitzpatrick ,Cella, Harper & Scinto
Gambel Phillip
Kyowa Hakko Kogyo Co. Ltd.
Ouspenski Ilia
LandOfFree
Recombinant antibody and antibody fragment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant antibody and antibody fragment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antibody and antibody fragment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3556850